Abstracts tagged "pain"

Abstract Number: 2089 • 2019 ACR/ARP Annual Meeting
Restricting Activity to Evade Knee Symptoms Is Associated with Worse Physical Function and Radiographic Osteoarthritis
Louise Thoma¹, Jason Jakiela ², Hiral Master ¹, Dana Voinier ², Meredith Christiansen ² and Daniel White ¹, ¹University of Delaware, Newark, DE, ²University of Delaware, Newark
Background/Purpose: Activity restriction (i.e. limiting or avoiding normal activity) is a common strategy to reduce, and sometimes eliminate, knee symptoms. Knee symptoms, such as pain,…
Abstract Number: 2171 • 2019 ACR/ARP Annual Meeting
Functional Exercise for Adults with Chronic Nonspecific Low Back Pain
Emilia Moreira¹, Anamaria Jones ¹, Eider Lima ¹, Fabio Jennings ² and Jamil Natour ², ¹Federal University of Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ²Federal University of São Paulo, São Paulo, Brazil
Background/Purpose: To assess the effectiveness of a functional exercise program for pain, functional capacity, general health, kinesiophobia, medication consumption and patient satisfaction in adults with chronic…
Abstract Number: 2183 • 2019 ACR/ARP Annual Meeting
Relation of Intra-Articular Knee Mineralization on CT to Knee Pain in People with or at Risk of Knee Osteoarthritis
Tuhina Neogi¹, John Lynch ², Mohamed Jarraya ³, David Felson ⁴, Na Wang ¹, Michael Nevitt ², James Torner ⁵, Beth Lewis ⁶ and Ali Guermazi ¹, ¹Boston University School of Medicine, Boston, MA, ²University of California at San Francisco, San Francisco, CA, ³Mercy Catholic Medical Center, Darby, ⁴Boston University School of Medicine, Department of Rheumatology, Boston, ⁵University of Iowa at Iowa City, Iowa City, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Intra-articular (i.a.) calcium crystal deposition is common in knee osteoarthritis (OA), particularly in end-stage disease. It is possible that low-grade inflammation related to crystals…
Abstract Number: 197 • 2019 ACR/ARP Annual Meeting
The Relationship Between Pain and Patient Demographics, Clinical Features, and Health Outcomes in a Cohort of Rheumatoid Arthritis Patients Recruited and Studied Using a Mobile Application
Harriet Dickinson ¹, Yunhao Liu ² and Rachel Williams³, ¹GSK, Stevenage, United Kingdom, ²GSK, Upper providence, ³GSK, Upper Providence, PA
Background/Purpose: Pain is one of the most pressing problems for Rheumatoid Arthritis (RA) patients and contributes substantially towards fatigue and disability. Experiences of pain in…
Abstract Number: 912 • 2019 ACR/ARP Annual Meeting
Co-morbidities Associated with Discordance Between Structural Severity and Pain in Osteoarthritis: Implications for Clinical Trial Design in OA – a Post-Hoc Analysis of Data from Two Randomized Controlled Trials
Jonathan Bjerre-Bastos¹, Inger Byrjalsen ², Morten Karsdal ³, Jeppe Andersen ¹ and Asger Bihlet ¹, ¹Nordic Bioscience Clinical Development, Herlev, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Nordic Bioscience, Copenhagen, Denmark
Background/Purpose: Development of new disease-modifying drugs in osteoarthritis (DMOADs) has proven difficult and is complicated by heterogeneous study populations and insensitive endpoints of structural change,…
Abstract Number: 1216 • 2019 ACR/ARP Annual Meeting
Pilot, Randomized, Double-Blinded, Placebo Controlled Efficacy AndSafety Study of a Transdermal Alkalinizing and Pain Relieving Treatment ForAcute Gout Flare
Smitha Reddy¹, Ray Mabaquiao ² and Lisa Misell ³, ¹Arthritis Care and Research Inc., Poway, CA, ²Triwest Research, El Cajon, CA, ³Dyve Biosciences, San Diego, CA
Background/Purpose: Gout is characterized by a build-up of uric acid crystals in and around the joints. Uric acid crystal formation and dissolution is affected by…
Abstract Number: 1249 • 2019 ACR/ARP Annual Meeting
Pelvic Congestion Syndrome, an Uncommon Cause of Osteoarticular Pain
Mireia Castillo-Vilella¹, Jose Luis Tandaipan ², Laura Berbel ³, Lluís Moga ³, Georgina Salvador ³, Silvia Martínez-Pardo ³ and Nuria Giménez ³, ¹Hospital Universitari Sagrat Cor, Barcelona, Spain, ²Hospital Universitari Mutua Terrassa, Terrassa, Spain, ³Hospital Universitari Mútua Terrassa, Terrassa
Background/Purpose: Background: The pelvic congestion syndrome (PCS) is an under and often misdiagnosed entity that appears more frequently in premenopausal age and multiparous women. The…
Abstract Number: 1821 • 2019 ACR/ARP Annual Meeting
Tildrakizumab Efficacy for Psoriatic Arthritis: 24-week Analysis of Swollen and Tender Joint Counts and Pain
Ana-Maria Orbai ¹, Rocco Ballerini ², Richard C. Chou ³, Stephen Rozzo ², Alan Mendelsohn² and Luis R. Espinoza ⁴, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ³University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁴Section of Rheumatology, LSU Health Sciences Center, New Orleans, LA, New Orleans, LA
Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved to treat moderate-to-severe plaque psoriasis. A randomized, double-blind, multidose, placebo (PBO)-controlled, phase 2b study (NCT02980692)…
Abstract Number: 1392 • 2018 ACR/ARHP Annual Meeting
Decreased Injection Site Pain Associated with New Etanercept Formulation in Patients with Rheumatoid Arthritis or Psoriatic Arthritis
Stanley Cohen¹, Ahmed Samad², Elaine Karis², Bradley S. Stolshek², Mona Trivedi², Hao Zhang², Girish A. Aras², Greg Kricorian² and James Chung², ¹Metroplex Clinical Research Center, Dallas, TX, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Injection site pain (ISP) is a component of the patient experience with injectable drugs. A new formulation of etanercept was developed to reduce ISP.…
Abstract Number: 1558 • 2018 ACR/ARHP Annual Meeting
Intravenous Immunoglobulin Efficacy for Primary Sjögren’s Syndrome Associated Small Fiber Neuropathy
Antoine Gaillet¹, Karine Champion¹, Jean-Pascal Lefaucheur², Herve Trout³, Jean-François Bergmann¹ and Damien Sène⁴, ¹Internal Medicine Department, Lariboisière Hospital, Paris, France, ²Clinical Neurophysiology Unit,, Henri-Mondor Hospital, Créteil, France, ³Pharmacy Department, Lariboisière Hospital, Paris, France, ⁴Lariboisière Hospital, Paris Diderot University, Paris, France
Background/Purpose: To analyze the efficacy and tolerance of intravenous immunoglobulin (IVIG) therapy in 11 patients with primary Sjögren's syndrome (pSS)-associated small-fiber neuropathy (SFN).Methods: Retrospective, single-center…
Abstract Number: 1644 • 2018 ACR/ARHP Annual Meeting
Improvement in Morning Stiffness in Subjects with Psa Is Associated with Improvements in Pain, Physical Function, and Patient Global Response to Treatment
Ana-Maria Orbai¹, Jessica Walsh², Peter Nash³, Lichen Teng⁴, Benoit Guerette⁴ and Rieke Alten⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Utah School of Medicine, Salt Lake City, UT, USA, Salt Lake City, UT, ³University of Queensland, Brisbane, Australia, ⁴Celgene Corporation, Summit, NJ, ⁵Schlosspark-Klinik University Medicine, Berlin, Germany
Background/Purpose: Stiffness is an important component of inflammatory arthritis and plays a role in PsA flare. Patients with inflammatory arthritis report difficulty with activities, “slowing…
Abstract Number: 1918 • 2018 ACR/ARHP Annual Meeting
Defining Pain That Does Not Interfere with Activities Among Rheumatoid Arthritis (RA) Patients
Yvonne C. Lee¹, Patricia Katz^2,3, Amanda Quebe⁴, Luna Sun⁴, Himanshu Patel⁴, Carol L. Gaich⁴, Natalie Boytsov⁴ and Kaleb Michaud^5,6, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Forward/National Data Bank for Rheumatic Diseases, Wichita, KS, ³University of California San Francisco, San Francisco, CA, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: RA patients differ in the degree to which pain interferes with function. To improve function, an understanding of this diversity is needed. Our objectives…
Abstract Number: 1922 • 2018 ACR/ARHP Annual Meeting
Characterization of the Pharmacology and Pharmacokinetics of Cntx-4975, a High-Purity, Synthetic Trans-Capsaicin in Clinical Development for the Treatment of Moderate to Severe OA Knee Pain
James Campbell, Randall Stevens and Peter Hanson, Centrexion Therapeutics, Boston, MA
Background/Purpose: CNTX-4975, a highly purified, synthetic trans-capsaicin and long-acting, non-opioid analgesic in phase 3 trials for moderate to severe OA knee pain, has demonstrated safety…
Abstract Number: 2531 • 2018 ACR/ARHP Annual Meeting
Assessment of Pain Relief with Baricitinib By Treatment History in Patients with Refractory Rheumatoid Arthritis
Janet E. Pope¹, Amanda Quebe², Baojin Zhu², Luna Sun², Carol L. Gaich², Francesco de Leonardis², Anabela Cardoso² and Mark C. Genovese³, ¹St. Joseph's Health Care, Divsion of Rheumatology, London, ON, Canada, ²Eli Lilly and Company, Indianapolis, IN, ³Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Baricitinib (BARI) 2 mg and 4 mg once daily demonstrated significant clinical improvements compared to placebo in the phase 3 study of RA patients…
Abstract Number: 2563 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of a Potent and Highly Selective Oral Tyrosine Kinase 2 Inhibitor, BMS-986165, in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase II, Randomized, Placebo-Controlled Trial
Kim A Papp¹, Kenneth B. Gordon², Diamant Thaçi³, Akimichi Morita⁴, Melinda Gooderham⁵, Peter Foley^6,7,8, Ihab G. Girgis⁹, Sudeep Kundu⁹ and Subhashis Banerjee⁹, ¹Clinical Research and Probity Medical Research, Waterloo, ON, Canada, ²Medical College of Wisconsin, Milwaukee, WI, ³University of Luebeck, Luebeck, Germany, ⁴Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁵SKiN Centre for Dermatology, Queen’s University and Probity Medical Research, Peterborough, ON, Canada, ⁶The University of Melbourne, Melbourne, Australia, ⁷St Vincent’s Hospital Melbourne & Probity Medical Research, Melbourne, Australia, ⁸Skin & Cancer Foundation Inc, Melbourne, Australia, ⁹Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: BMS-986165, a potent and highly selective oral tyrosine kinase 2 inhibitor, inhibits signal transducer and activator of transcription (STAT)-dependent signalling pathways of interleukin-23 and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].